Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated at Wedbush

Wedbush started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Friday morning, Marketbeat.com reports. The firm issued an outperform rating and a $11.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 18th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $17.50.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $6.86 on Friday. The company has a market capitalization of $374.76 million, a PE ratio of 9.66 and a beta of 0.89. Voyager Therapeutics has a 52-week low of $5.19 and a 52-week high of $11.72. The business’s fifty day moving average is $6.51 and its 200 day moving average is $7.29.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter last year, the firm posted ($0.59) EPS. On average, sell-side analysts forecast that Voyager Therapeutics will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter worth about $74,000. SG Americas Securities LLC bought a new stake in shares of Voyager Therapeutics in the second quarter worth about $85,000. Victory Capital Management Inc. increased its holdings in Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC bought a new position in Voyager Therapeutics during the 2nd quarter valued at approximately $128,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.